Why GW Pharmaceuticals PLC Shares Skyrocketed

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of GW Pharmaceuticals , a biopharmaceutical company engaged in the discovery of cannabinoids and effecting biologic pathway change through use of those cannabinoids, surged as much as 17% after announcing physician reports on investigational treatment-resistant epilepsy drug epidiolex in children and young adults.

So what: According to its early morning press release, of the 27 children and young adults evaluated by physicians in its study, which included nine cases of Dravet syndrome, patients that did respond to epidiolex demonstrated a high propensity to have a 50% or greater reduction in seizures, with 15% of patients going the entire 12-week treatment course seizure-free. As noted, mean overall reduction in seizure frequency from baseline was 44%, with 41% of all patients obtaining at least a 70% reduction in seizure frequency. Utilizing additional safety data from another study which allowed a look at a patient pool of 62 children and young adults, 80% of all adverse events were considered mild-to-moderate with no patient withdrawals due to adverse events. GW anticipates moving its epidiolex development program into phase 2/3 by the latter half of this year.

Now what: This is positive news for GW Pharmaceuticals and would appear to signal that epidiolex is, to some degree, effective at reducing seizure frequency, especially in Dravet syndrome patients where the average seizure reduction percentages were even higher. But as I've noted in the past, GW's potential on paper and its current valuation have never aligned. Sativex, its multiple sclerosis-related spasticity treatment has sold poorly throughout much of Europe, and the company could face backlash from physicians who are simply unwilling to prescribe something derived from the cannabis plant. Marijuana stocks are certainly all the rage, and none has more potential than GW Pharmaceuticals; I will give it that. However, at a valuation of nearly $1.6 billion, with zero guarantees that it'll infiltrate the highly profitable U.S. markets, I'd suggest passing on GW here.

GW Pharmaceuticals may have soared today, but keeping up with this top stock might prove impossible! 
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

The article Why GW Pharmaceuticals PLC Shares Skyrocketed originally appeared on Fool.com.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story